There were no effects on postnatal behavioral and reproductive development discount 80 mg top avana mastercard. There are no adequate and well-controlled studies in pregnant women purchase top avana 80 mg without prescription. It is not known whether aripiprazole can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Aripiprazole should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus. The effect of aripiprazole on labor and delivery in humans is unknown. Aripiprazole was excreted in milk of rats during lactation. It is not known whether aripiprazole or its metabolites are excreted in human milk. It is recommended that women receiving aripiprazole should not breast-feed. Safety and effectiveness in pediatric patients with Schizophrenia were established in a 6-week, placebo-controlled clinical trial in 202 pediatric patients aged 13 to 17 years [see Indications and Usage (1. Although maintenance efficacy in pediatric patients has not been systematically evaluated, maintenance efficacy can be extrapolated from adult data along with comparisons of aripiprazole pharmacokinetic parameters in adult and pediatric patients. Safety and effectiveness in pediatric patients with Bipolar Mania were established in a 4-week, placebo-controlled clinical trial in 197 pediatric patients aged 10 to 17 years [see Indications and Usage (1. Although maintenance efficacy in pediatric patients has not been systematically evaluated, maintenance efficacy can be extrapolated from adult data along with comparisons of aripiprazole pharmacokinetic parameters in adult and pediatric patients. The efficacy of adjunctive ABILIFY (aripiprazole) with concomitant lithium or valproate in the treatment of manic or mixed episodes in pediatric patients has not been systematically evaluated. However, such efficacy and lack of pharmacokinetic interaction between aripiprazole and lithium or valproate can be extrapolated from adult data, along with comparisons of aripiprazole pharmacokinetic parameters in adult and pediatric patients. The pharmacokinetics of aripiprazole and dehydro-aripiprazole in pediatric patients 10 to 17 years of age were similar to those in adults after correcting for the differences in body weights. In formal single-dose pharmacokinetic studies (with aripiprazole given in a single dose of 15 mg), aripiprazole clearance was 20% lower in elderly ( ?-U 65 years) subjects compared to younger adult subjects (18 to 64 years). There was no detectable age effect, however, in the population pharmacokinetic analysis in Schizophrenia patients. Also, the pharmacokinetics of aripiprazole after multiple doses in elderly patients appeared similar to that observed in young, healthy subjects. No dosage adjustment is recommended for elderly patients [see also BOXED WARNING and WARNINGS AND PRECAUTIONS (5. Placebo-controlled studies of oral aripiprazole in Schizophrenia, Bipolar Mania, or Major Depressive Disorder did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Of the 749 patients treated with aripiprazole injection in clinical trials,99 (13%) were ?-U 65 years old and 78 (10%) were ?-U 75 years old. Placebo-controlled studies of aripiprazole injection in patients with agitation associated with Schizophrenia or Bipolar Mania did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. If the prescriber elects to treat such patients with ABILIFY, vigilance should be exercised. In patients with severe renal impairment (creatinine clearance < 30 mL/min), Cmax of aripiprazole (given in a single dose of 15 mg) and dehydro-aripiprazole increased by 36% and 53%, respectively, but AUC was 15% lower for aripiprazole and 7% higher for dehydro-aripiprazole. Renal excretion of both unchanged aripiprazole and dehydro-aripiprazole is less than 1% of the dose. No dosage adjustment is required in subjects with renal impairment. In a single-dose study (15 mg of aripiprazole) in subjects with varying degrees of liver cirrhosis (Child-Pugh Classes A, B, and C), the AUC of aripiprazole, compared to healthy subjects, increased 31% in mild HI, increased 8% in moderate HI, and decreased 20% in severe HI. None of these differences would require dose adjustment. Cmax and AUC of aripiprazole and its active metabolite, dehydroaripiprazole, are 30% to 40% higher in women than in men, and correspondingly, the apparent oral clearance of aripiprazole is lower in women. These differences, however, are largely explained by differences in body weight (25%) between men and women. No dosage adjustment is recommended based on gender. Although no specific pharmacokinetic study was conducted to investigate the effects of race on the disposition of aripiprazole, population pharmacokinetic evaluation revealed no evidence of clinically significant race-related differences in the pharmacokinetics of aripiprazole. Based on studies utilizing human liver enzymes in vitro, aripiprazole is not a substrate for CYP1A2 and also does not undergo direct glucuronidation. Smoking should, therefore, not have an effect on the pharmacokinetics of aripiprazole. Consistent with these in vitro results, population pharmacokinetic evaluation did not reveal any significant pharmacokinetic differences between smokers and nonsmokers. No dosage adjustment is recommended based on smoking status. ABILIFY (aripiprazole) is not a controlled substance. Aripiprazole has not been systematically studied in humans for its potential for abuse, tolerance, or physical dependence. In physical dependence studies in monkeys, withdrawal symptoms were observed upon abrupt cessation of dosing. While the clinical trials did not reveal any tendency for any drug-seeking behavior, these observations were not systematic and it is not possible to predict on the basis of this limited experience the extent to which a CNS-active drug will be misused, diverted, and/or abused once marketed. Consequently, patients should be evaluated carefully for a history of drug abuse,and such patients should be observed closely for signs of ABILIFY misuse or abuse (eg, development of tolerance, increases in dose, drug-seeking behavior). MedDRA terminology has been used to classify the adverse reactions. A total of 76 cases of deliberate or accidental overdosage with oral aripiprazole have been reported worldwide. These include overdoses with oral aripiprazole alone and in combination with other substances. Of the 44 cases with known outcome, 33 cases recovered without sequelae and one case recovered with sequelae (mydriasis and feeling abnormal). The largest known case of acute ingestion with a known outcome involved 1080 mg of oral aripiprazole (36 times the maximum recommended daily dose) in a patient who fully recovered. Included in the 76 cases are 10 cases of deliberate or accidental overdosage in children (age 12 and younger) involving oral aripiprazole ingestions up to 195 mg with no fatalities. Common adverse reactions (reported in at least 5% of all overdose cases) reported with oral aripiprazole overdosage (alone or in combination with other substances) include vomiting, somnolence, and tremor. Other clinically important signs and symptoms observed in one or more patients with aripiprazole overdoses (alone or with other substances) include acidosis, aggression, aspartate aminotransferase increased, atrial fibrillation, bradycardia, coma, confusional state, convulsion, blood creatine phosphokinase increased, depressed level of consciousness, hypertension, hypokalemia, hypotension, lethargy, loss of consciousness, QRS complex prolonged, QT prolonged, pneumonia aspiration, respiratory arrest, status epilepticus, and tachycardia. No specific information is available on the treatment of overdose with aripiprazole. An electrocardiogram should be obtained in case of overdosage and if QT interval prolongation is present, cardiac monitoring should be instituted. Otherwise, management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. Close medical supervision and monitoring should continue until the patient recovers. Charcoal: In the event of an overdose of ABILIFY,an early charcoal administration may be useful in partially preventing the absorption of aripiprazole. Administration of 50 g of activated charcoal, one hour after a single 15 mg oral dose of aripiprazole, decreased the mean AUC and CHemodialysiss: Although there is no information on the effect of hemodialysis in treating an overdose with aripiprazole, hemodialysis is unlikely to be useful in overdose management since aripiprazole is highly bound to plasma proteins. Aripiprazole is a psychotropic drug that is available as ABILIFY (aripiprazole) Tablets, ABILIFY DISCMELT (aripiprazole) Orally Disintegrating Tablets, ABILIFY (aripiprazole) Oral Solution, and ABILIFY (aripiprazole) Injection, a solution for intramuscular injection. The empirical formula is C H Cl N O and 23 27 2 3 2 its molecular weight is 448. The chemical structure is:ABILIFY Tablets are available in 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg strengths. Inactive ingredients include cornstarch, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, and microcrystalline cellulose. Colorants include ferric oxide (yellow or red) and FD&C Blue No.
Is your life full of work-related stressors that affect your ability to sleep purchase top avana 80mg amex, diet and health? Unhealthy work addictions are best dealt with by counselors and therapists who specialize in workplace problems top avana 80 mg cheap. But like all addictions, workaholism gets worse with time. If you are a work addict, seeking help in the early stages may save you many years of unhappiness. Mid- and senior-level managers were asked to estimate the amount of time they spent on the job each week. The productivity and effectiveness of their work was then evaluated. The study found that highly effective managers worked an average of 52 hours a week, while less productive managers averaged 70 hours of work per week. Common standardized tests were administered to evaluate anxiety and depression levels in both groups of managers. Not surprisingly, managers who put in more hours and were considered less productive suffered from significantly greater depression and anxiety. They also reported twice the level of stress-related health problems, such as stomach ailments, headaches, lower-back pain and common colds. In fact, unproductive managers were absent from work almost three times as often as productive managers. In this performance-driven economy, working hard is necessary to succeed on the job. But when work consumes you and makes you unhappy, you must face your addiction, perhaps with professional help. You can expect the emotional, monetary and personal benefits of a happy career. Glicken is a professor of social work at California State University in San Bernardino, and a frequent contributor to the National Business Employment Weekly. Crystal methamphetamine effects can be devastating both on the addict and those around them. Methamphetamine is thought to be one of the most addictive drugs and quickly shows detrimental short term effects of meth. The long term effects of meth can include heart, liver and brain damage and are sometimes lethal. Crystal methamphetamine effects are variable depending on a number of factors, including the following:How long the person has been using methAny pre-existing psychiatric disordersAny additional drugs, supplements or alcohol consumedThe effects of meth are seen both on the body and in the mind of the addict. Both types of crystal methamphetamine effects can be equally serious. Short term effects of meth on the body are easier to recover from, but in rare cases can still result in death. Typical short term effects of meth on the body include:Compulsive behavior, a need to repeat the same actionAggression, violent behaviorLack of sleepiness, insomniaIncrease in blood pressure, heart rate and body temperaturePalpitations irregular heart beatDiarrhea, nausea, vomitingOnce the user begins meth withdrawal, the following short term meth effects can be seen:While effects of meth on the body can be seen, effects of meth on the brain are also taking place. One of the major effects of meth on the brain centers around a brain chemical, a neurotransmitter, known as dopamine. Dopamine is one of the major neurotransmitters that signal pleasure in the brain. When methamphetamines are used, the brain releases abnormally large amounts of dopamine. Effects of meth on the brain include many other chemical changes in the brain. Short term effects of meth on the brain include: Increased energy and alertnessAgitation, irritability, sudden mood changesAnxiety, panic, paranoia. Most crystal methamphetamine effects will decrease over time, but in some cases severe effects of meth can be permanent. One of the commonly seen long term side effects of meth is known as "meth mouth. Some of the reasons for meth mouth include: Preference of meth addicts for sugar such as sugary carbonated drinksTeeth grinding and clenching, often seen as a part of withdrawalOther long term effects of meth occur in both the body and the brain. Some of the long term effects of meth are thought to be caused due to the prolonged lack of dopamine in the brain. And the need for meth addiction treatment continues to grow: In 2002 admissions into methamphetamine treatment programs was five times that of 1992 in the US. Meth addiction treatment is particularly challenging, as meth addicts use meth for an average of seven years before seeking treatment for meth addiction. These meth addicts then, are more permanently attached to the drug culture and have a much harder time getting out of that culture in order to facilitate successful treatment for meth addiction. Long-term, structured methamphetamine treatment programs which involve frequent contact show the best success at meth addiction treatment. As meth treatment professionals began to realize that it was extremely difficult to succeed in meth addiction treatment, new methamphetamine treatments have been developed to get addicts off the drug and to keep them off meth. The most effective treatments for meth addiction are now based on cognitive behavioral approaches. Components of treatment for meth addiction typically include:Continuing treatment plansThe Matrix Model of meth treatment has been developed over 20 years and is used at the Matrix Institute of Addictions and throughout the U. The Matrix Model of meth addiction treatment has been studied and demonstrates more program completions and reduced methamphetamine use when compared to standard available meth treatment. Because relapse is so common, the Matrix Model of treatment for meth addiction is designed to be intensive, outpatient meth treatment over 2-6 months. While this may seem like a long time for methamphetamine treatment, it is short compared to the amount of time the meth addict has been addicted to drugs. The Matrix Model of treatment for meth addiction includes: Motivational Interviewing (MI) - Also evidence-based, this non-confrontational therapy focuses on client respect and help in moving forward in treatment and in life. The therapist and client form a positive relationship to foster success. Family Involvement - Family and friends are encouraged to participate. Education - Because the Matrix Model is a scientific approach to methamphetamine treatment, the model also educates about drugs, addiction and the latest addiction research is easy-to-understand ways. Contingency Management - Positive behaviors are reinforced during treatment for meth addiction and plans are made in advance of any possible relapse. Continuing Care - Meth addicts who stay connected to the methamphetamine treatment environment have better long-term outcomes. Meth addiction treatment is difficult, but not impossible. Working with this brain damage requires special methamphetamine considerations such as:Memory and concentration problemsTime-management and chaotic life issuesCo-occurring addictionsCo-occurring mental illnessMeth addiction is difficult addiction to break. This is often because meth addicts are addicted to methamphetamines for years before seeking meth addiction treatment. A meth rehab center can help someone with a drug-based lifestyle receive the structure and support they need to start moving their drug-free life forward. Meth rehab centers are focused on everything a person going through meth rehab needs. Typical services at a meth rehab center include:Medical assistance during initial meth rehabTherapy, both individual and groupEducation on addiction and drugsTeaching of life, relapse and stress tolerance skillsOngoing meth rehab supportA meth rehab center may offer both inpatient and outpatient meth rehab. Both types of meth rehab can be useful but individual circumstances may make an individual prefer one over the other. Cost is often a factor in deciding type of meth rehab as inpatient meth rehab can be very expensive. For inpatient meth rehab, the addict lives at the meth rehab center and staff are available for assistance 24-hours a day. Inpatient meth rehab stays may happen at the beginning of meth rehab and then the addict transitions to outpatient meth rehab. Inpatient meth rehab has the following advantages:Addict is removed from potentially unsafe environmentAddict is removed from influences that may cause them to use methAddict is supported 24-hours a day both physically and psychologicallyAddict can focus only on meth rehab and not on the worries of everyday lifeAddict is provided with a healthy living environment, including a healthy diet, to improve the physical health of the addict which has typically vastly diminished (read: side effects of meth )Outpatient meth rehab is often chosen by those who have a safe place to stay each night. Outpatient meth rehab is typically intensive and requires meth rehab activities be completed daily. Usually, the addict spends time at the meth rehab center at least three days a week. When not at the meth rehab center, they attend support groups elsewhere. Even in outpatient meth rehab, the addict is required to take drug tests ensuring they have not been using meth or any other drugs.
In patients with type 2 diabetes administered sitagliptin 100 mg (N=81) or sitagliptin 200 mg (N=63) daily buy top avana 80 mg without a prescription, there were no meaningful changes in QTc interval based on ECG data obtained at the time of expected peak plasma concentration order 80mg top avana mastercard. The results of a bioequivalence study in healthy subjects demonstrated that the Janumet (sitagliptin/metformin HCl) 50 mg/500 mg and 50 mg/1000 mg combination tablets are bioequivalent to co-administration of corresponding doses of sitagliptin (JANUVIA) and metformin hydrochloride as individual tablets. The absolute bioavailability of sitagliptin is approximately 87%. Co-administration of a high-fat meal with sitagliptin had no effect on the pharmacokinetics of sitagliptin. The absolute bioavailability of a metformin hydrochloride 500-mg tablet given under fasting conditions is approximately 50-60%. Studies using single oral doses of metformin hydrochloride tablets 500 mg to 1500 mg, and 850 mg to 2550 mg, indicate that there is a lack of dose proportionality with increasing doses, which is due to decreased absorption rather than an alteration in elimination. Food decreases the extent of and slightly delays the absorption of metformin, as shown by approximately a 40% lower mean peak plasma concentration (C), a 25% lower area under the plasma concentration versus time curve (AUC), and a 35-minute prolongation of time to peak plasma concentration (T) following administration of a single 850-mg tablet of metformin with food, compared to the same tablet strength administered fasting. The clinical relevance of these decreases is unknown. The mean volume of distribution at steady state following a single 100-mg intravenous dose of sitagliptin to healthy subjects is approximately 198 liters. The fraction of sitagliptin reversibly bound to plasma proteins is low (38%). The apparent volume of distribution (V/F) of metformin following single oral doses of metformin hydrochloride tablets 850 mg averaged 654 a 358 L. Metformin is negligibly bound to plasma proteins, in contrast to sulfonylureas, which are more than 90% protein bound. Metformin partitions into erythrocytes, most likely as a function of time. At usual clinical doses and dosing schedules of metformin hydrochloride tablets, steady-state plasma concentrations of metformin are reached within 24-48 hours and are generallyC]sitagliptin oral dose, approximately 16% of the radioactivity was excreted as metabolites of sitagliptin. Six metabolites were detected at trace levels and are not expected to contribute to the plasma DPP-4 inhibitory activity of sitagliptin. In vitro studies indicated that the primary enzyme responsible for the limited metabolism of sitagliptin was CYP3A4, with contribution from CYP2C8. Intravenous single-dose studies in normal subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been identified in humans) nor biliary excretion. Following administration of an oral [C]sitagliptin dose to healthy subjects, approximately 100% of the administered radioactivity was eliminated in feces (13%) or urine (87%) within one week of dosing. The apparent terminal tfollowing a 100-mg oral dose of sitagliptin was approximately 12. Elimination of sitagliptin occurs primarily via renal excretion and involves active tubular secretion. Sitagliptin is a substrate for human organic anion transporter-3 (hOAT-3), which may be involved in the renal elimination of sitagliptin. The clinical relevance of hOAT-3 in sitagliptin transport has not been established. Sitagliptin is also a substrate of p-glycoprotein, which may also be involved in mediating the renal elimination of sitagliptin. However, cyclosporine, a p-glycoprotein inhibitor, did not reduce the renal clearance of sitagliptin. Following oral administration, approximately 90% of the absorbed drug is eliminated via the renal route within the first 24 hours, with a plasma elimination half-life of approximately 6. In blood, the elimination half-life is approximately 17. An approximately 2-fold increase in the plasma AUC of sitagliptin was observed in patients with moderate renal insufficiency, and an approximately 4-fold increase was observed in patients with severe renal insufficiency including patients with ESRD on hemodialysis, as compared to normal healthy control subjects. In patients with decreased renal function (based on measured creatinine clearance), the plasma and blood half-life of metformin is prolonged and the renal clearance is decreased in proportion to the decrease in creatinine clearance. In patients with moderate hepatic insufficiency (Child-Pugh score 7 to 9), mean AUC and Cof sitagliptin increased approximately 21% and 13%, respectively, compared to healthy matched controls following administration of a single 100-mg dose of sitagliptin. These differences are not considered to be clinically meaningful. There is no clinical experience in patients with severe hepatic insufficiency (Child-Pugh score >9). No pharmacokinetic studies of metformin have been conducted in patients with hepatic insufficiency. Gender had no clinically meaningful effect on the pharmacokinetics of sitagliptin based on a composite analysis of Phase I pharmacokinetic data and on a population pharmacokinetic analysis of Phase I and Phase II data. Metformin pharmacokinetic parameters did not differ significantly between normal subjects and patients with type 2 diabetes when analyzed according to gender. Similarly, in controlled clinical studies in patients with type 2 diabetes, the antihyperglycemic effect of metformin was comparable in males and females. When the effects of age on renal function are taken into account, age alone did not have a clinically meaningful impact on the pharmacokinetics of sitagliptin based on a population pharmacokinetic analysis. Elderly subjects (65 to 80 years) had approximately 19% higher plasma concentrations of sitagliptin compared to younger subjects. Limited data from controlled pharmacokinetic studies of metformin in healthy elderly subjects suggest that total plasma clearance of metformin is decreased, the half life is prolonged, and Cis increased, compared to healthy young subjects. From these data, it appears that the change in metformin pharmacokinetics with aging is primarily accounted for by a change in renal function (see GLUCOPHAGEprescribing information: CLINICAL PHARMACOLOGY, Special Populations, Geriatrics). Janumet treatment should not be initiated in patients ?-U80 years of age unless measurement of creatinine clearance demonstrates that renal function is not reduced [see Warnings and Precautions ]. No studies with Janumet have been performed in pediatric patients. Race had no clinically meaningful effect on the pharmacokinetics of sitagliptin based on a composite analysis of available pharmacokinetic data, including subjects of white, Hispanic, black, Asian, and other racial groups. No studies of metformin pharmacokinetic parameters according to race have been performed. In controlled clinical studies of metformin in patients with type 2 diabetes, the antihyperglycemic effect was comparable in whites (n=249), blacks (n=51), and Hispanics (n=24). Body mass index had no clinically meaningful effect on the pharmacokinetics of sitagliptin based on a composite analysis of Phase I pharmacokinetic data and on a population pharmacokinetic analysis of Phase I and Phase II data. Sitagliptin and Metformin hydrochlorideCo-administration of multiple doses of sitagliptin (50 mg) and metformin (1000 mg) given twice daily did not meaningfully alter the pharmacokinetics of either sitagliptin or metformin in patients with type 2 diabetes. Pharmacokinetic drug interaction studies with Janumet have not been performed; however, such studies have been conducted with the individual components of Janumet (sitagliptin and metformin hydrochloride). In Vitro Assessment of Drug InteractionsSitagliptin is not an inhibitor of CYP isozymes CYP3A4, 2C8, 2C9, 2D6, 1A2, 2C19 or 2B6, and is not an inducer of CYP3A4. Sitagliptin is a p-glycoprotein substrate, but does not inhibit p-glycoprotein mediated transport of digoxin. Based on these results, sitagliptin is considered unlikely to cause interactions with other drugs that utilize these pathways. Sitagliptin is not extensively bound to plasma proteins. Therefore, the propensity of sitagliptin to be involved in clinically meaningful drug-drug interactions mediated by plasma protein binding displacement is very low. In Vivo Assessment of Drug InteractionsEffect of Sitagliptin on Other DrugsIn clinical studies, as described below, sitagliptin did not meaningfully alter the pharmacokinetics of metformin, glyburide, simvastatin, rosiglitazone, warfarin, or oral contraceptives, providing in vivo evidence of a low propensity for causing drug interactions with substrates of CYP3A4, CYP2C8, CYP2C9, and organic cationic transporter (OCT). Digoxin: Sitagliptin had a minimal effect on the pharmacokinetics of digoxin. Clinically meaningful interactions would not be expected with other sulfonylureas (e. Simvastatin: Single-dose pharmacokinetics of simvastatin, a CYP3A4 substrate, was not meaningfully altered in subjects receiving multiple daily doses of sitagliptin. Therefore, sitagliptin is not an inhibitor of CYP3A4-mediated metabolism. Thiazolidinediones: Single-dose pharmacokinetics of rosiglitazone was not meaningfully altered in subjects receiving multiple daily doses of sitagliptin, indicating that sitagliptin is not an inhibitor of CYP2C8-mediated metabolism. Warfarin: Multiple daily doses of sitagliptin did not meaningfully alter the pharmacokinetics, as assessed by measurement of S(-) or R(+) warfarin enantiomers, or pharmacodynamics (as assessed by measurement of prothrombin INR) of a single dose of warfarin. Because S(-) warfarin is primarily metabolized by CYP2C9, these data also support the conclusion that sitagliptin is not a CYP2C9 inhibitor.
Bullying at School: What We Know and What We Can Do cheap 80 mg top avana with visa. Group view on victimization: Empirical findings and their implications top avana 80 mg amex. Peer Harassment in School: The Plight of the Vulnerable and Victimized. Journal of the American Medical Association, 285(16), 2094-2100. Source: The National Youth Violence Prevention Resource CenterSources: Kidshealth, The National Youth Violence Prevention Resource CenterThe Free Dictionary, Abuse:http://medical-dictionary. Oregon Counselling, About Domestic Violence Against Men: http://www. Domestic Violence legal definition of Domestic Violence. Domestic Violence synonyms by the Free Online Law Dictionary. Family Violence Law Center | A Future Without Domestic Violence. Retrieved May 21, 2012, fromDomestic Violence - Types of Domestic Abuse: Crime Victims Services - Arizona Department of Public Safety. Arizona Department of Public Safety (DPS), Arizona Highway Patrol - State of Arizona. Retrieved May 21, 2012, fromDomestic Violence and Abuse: Signs of Abuse and Abusive Relationships. Retrieved May 22, 2012, fromDomestic Violence-Signs of Domestic Violence. National CASA - Court Appointed Special Advocate Association - CASA for Children: Advocating for Abused and Neglected Children. Retrieved May 31, 2012, fromDomestic Violence and Abuse: Types, Signs, Symptoms, Causes, and Effects. Helpguide helps you help yourself to better mental and emotional health. Retrieved June 1, 2012, fromNational Coalition Against Domestic Violence. Retrieved June 1, 2012, fromDomestic Violence Meetup Groups - Domestic Violence Meetups. Domestic Violence Meetup Groups - Domestic Violence Meetups. Retrieved June 1, 2012, fromSafe Horizon:: Domestic Violence & Abuse. Safe Horizon: Moving victims of violence from crisis to confidence. Retrieved June 1, 2012, fromWhat is Dating Violence? Break the Cycle | Empowering Youth to End Dating Violence. ACADV - Alabama Coalition Against Domestic Violence Home Page. Divorce Support and Advice: Divorce Laws, Child Support, Custody, Divorce Lawyers. Retrieved June 3, 2012, fromDomestic Abuse Helpline for Men & Women - About the Domestic Abuse Helpline. Retrieved June 3, 2012, fromHelp in Your Area - National Domestic Violence Hotline. Morris Therapy | Morris Depression | Joliet, IL Depression | Ottawa, IL ADD/ADHD. National Network to End Domestic Violence | National Network to End Domestic Violence. Retrieved June 3, 2012, fromRecent Trends in Treating Domestic Violence Offenders | PsychologyDegreeGuide. Psychology Degree Guide | Search 6000+ Psychology Degree Programs. Victims Stay Silent on Sexual Assault | News | The Harvard Crimson. Home - UI Department of Public Safety - The University of Iowa. The New York Times - Breaking News, World News & Multimedia. Retrieved June 20, 2012, fromUSDOJ: Office on Violence Against Women. Retrieved June 20, 2012, from Sexual Assault Treatment: Therapy for Trauma HealingCognitive Processing Therapy for Sexual Assault. Welcome to the Medical University of South Carolina. Title 18 ??? Crimes and Criminal Procedure, Part I ??? Crimes, Chapter 109A ??? Sexual Abuse: http://www. Statutory Rape Definition and LawsStatutory Rape Laws by State. Office of the Assistant Secretary for Planning and Evaluation, HHS. Date Rape Drugs - What are they and how can you protect yourself?. Welcome to South Eastern Centre Against Sexual Assault. Beyond Rape: Rape Victims & Survivor Stories with The Plain Dealer -. Cleveland OH Local News, Breaking News, Sports & Weather - cleveland. Rape & Sexual Abuse Survivor Message Board, Support Forums & Chat Room. Stigma of rape | The Post and Courier | Charleston SC, News, Sports, Entertainment. The Post and Courier | Charleston SC, News, Sports, Entertainment. Rape (sexual assault) - overview: MedlinePlus Medical Encyclopedia. National Library of Medicine - National Institutes of Health. National Library of Medicine - National Institutes of Health. Fear of Public Speaking, Flying, Stage Fright, Phobias: Immediate Help. Psychology Today: Health, Help, Happiness + Find a Therapist. Psychology Today: Health, Help, Happiness + Find a Therapist. Myths About RapeBPS Research Digest: A biological mechanism that protects against rape?. Retrieved June 30, 2012, from http://bps-research-digest. Verbal and Physical Abuse Often Go Hand-in-HandEvans, P. The verbally abusive relationship: How to recognize it and how to respond. Physical health consequences of physical and psychological intimate partner violence. Psychological effects of partner abuse against men: a neglected research area.
By E. Dolok. Albright College.